Barbara Maglione’s path to becoming the Head of Research & Development at Farmaceutici Damor is anything but linear, and it is precisely this unconventional journey that defines her approach to science and leadership. Unlike many who enter pharmaceutical R&D directly from academia or research, Barbara began her career in sales—a field far removed from the lab benches and microscopes most people associate with drug discovery.
“At first, some people questioned why someone from sales would ever move into scientific research,” Barbara admits with a smile. “But for me, that experience was foundational. It taught me about the real-world impact of what we do. I was speaking with doctors and nurses every day, hearing their challenges, understanding the patients’ struggles. I could see, firsthand, how a new therapy could transform lives. That perspective is something you cannot learn in a lab.”
Despite her success in sales, Barbara’s passion for science never waned. She pursued a degree in molecular biology, immersing herself in the rigor of scientific inquiry while carrying forward the human-centered insights she had gained in the field. The combination of business acumen and scientific knowledge would soon become her defining strength.
“In sales, you develop the ability to communicate complex ideas clearly and solve problems on the fly,” she explains. “Molecular biology taught me precision, critical thinking, and how to ask the right questions. When I transitioned into leadership roles, I realized that the best leaders are those who can bridge these worlds—talking to a scientist about a molecular pathway as easily as you discuss market potential with a sales representative.”
Barbara’s rise within Farmaceutici Damor is a testament to the power of diverse experiences. Today, she leads one of the company’s most critical divisions, applying lessons from both her sales background and scientific expertise to guide research projects that aim to improve patient outcomes worldwide. Her journey underscores a crucial message for aspiring leaders: success often comes from combining skill sets that others might see as unrelated, but that together create something truly unique.
Balancing Innovation with Scientific Integrity
At Farmaceutici Damor, Barbara Maglione oversees the Research & Development division with a philosophy that combines vision, rigor, and responsibility. For her, true innovation does not exist in a vacuum—it must be grounded in scientific integrity and patient safety. Her guiding principle is simple yet powerful: “Good science is good business.”
“It’s more than just a slogan,” Barbara explains. “Every project we undertake is guided by that principle. Innovation is exciting, but if it isn’t backed by rigorous science and ethical responsibility, it doesn’t truly serve anyone—patients, physicians, or the broader healthcare system.”
Barbara has implemented several practices to ensure that Damor’s R&D projects maintain both excellence and reliability:
Robust Peer Review
Every research project at Damor, from its earliest conceptual stages to the analysis of final data, undergoes rigorous internal and external peer review. Barbara emphasizes that feedback and critique are not just encouraged—they are essential.
“We actively invite critique and challenge our own assumptions constantly,” she says. “This ensures that our research is sound, reproducible, and resilient to scrutiny.”
Clear, Unbiased Protocols
Before any study begins, Barbara ensures that the team establishes detailed protocols. These protocols define every step of the experiment, reducing bias and ensuring that results are meaningful and reproducible.
“It’s about transparency and precision,” she notes. “Clear protocols allow us to maintain credibility and trust—not just within our team, but with regulatory agencies, clinicians, and, most importantly, the patients who may benefit from our discoveries.”
Early and Frequent Regulatory Engagement
Rather than waiting until a project concludes, Barbara advocates for continuous engagement with regulatory bodies. This proactive approach ensures that the team remains aligned with industry standards and avoids costly delays.
“Early dialogue with regulators is invaluable,” she says. “It keeps us on track and allows us to anticipate challenges before they become problems.”
Through these measures, Barbara has built a culture at Damor where innovation and integrity coexist seamlessly. She believes that true leadership in R&D is not about choosing between speed and quality, but about finding ways to achieve both.
“Our goal is to push boundaries, but responsibly,” Barbara adds. “Every decision we make is weighed against the potential impact on patients and the broader scientific community. That’s the kind of balance that sets a company apart in today’s fast-paced pharmaceutical landscape.”
Cultivating Leadership
Barbara Maglione believes that leadership in pharmaceutical R&D is about more than managing projects—it’s about nurturing the qualities that allow a team to excel. For her, traits like foresight, adaptability, and empathy are not innate; they are cultivated through deliberate encouragement, mentorship, and a culture that celebrates learning.
Promoting Curiosity
Barbara encourages her team to look beyond the boundaries of their immediate work. “I ask my researchers to pay attention to what’s happening across the scientific community, to watch emerging trends, and to understand what competitors are exploring,” she explains. “Curiosity isn’t just about science—it’s about foresight. Knowing what’s coming allows us to prepare, innovate, and stay ahead.”
She believes that this broad perspective is especially important in a rapidly changing field like pharmaceuticals, where yesterday’s breakthrough can quickly become today’s baseline. By fostering curiosity, Barbara equips her team to anticipate opportunities and navigate challenges with insight rather than reaction.
Embracing Failure as a Learning Opportunity
In R&D, not every experiment succeeds, and Barbara has cultivated a mindset that sees failure as part of progress. “Every setback is a chance to learn,” she says. “If a study doesn’t go as planned, we analyze why, adjust, and move forward stronger. That’s how adaptability and resilience are built—by accepting challenges, learning from them, and applying those lessons immediately.”
This approach creates a culture where team members are encouraged to take calculated risks and pursue bold ideas, knowing that support and guidance are available even when experiments don’t yield immediate results.
Listening to Understand
Barbara emphasizes empathy as the cornerstone of effective leadership. “I tell my team to really listen—not just to hear words, but to understand perspectives, frustrations, and ideas,” she notes. “Empathy fosters collaboration, strengthens relationships, and ultimately improves our science.”
Her focus on empathy extends beyond the laboratory. Barbara works to ensure that her team feels valued, heard, and supported, which in turn inspires innovation and loyalty. By blending foresight, adaptability, and empathy, she has created an environment where creativity thrives alongside scientific discipline.
Barbara’s leadership style demonstrates that successful R&D is not just about knowledge—it’s about people. She has shown that a leader who cultivates curiosity, embraces failure, and listens with empathy can guide a team to achieve breakthroughs that might otherwise seem impossible.
The Bioarginina® Breakthrough
Among Barbara Maglione’s many achievements, her leadership during the development of Bioarginina® for COVID-19 sub-intensive care patients stands out as a defining moment in her career. At the height of the pandemic, hospitals around the world faced a critical challenge: patients who were severely ill but not yet requiring ventilators were at high risk of sudden deterioration.
“COVID-19 presented us with an urgent, unprecedented problem,” Barbara recalls. “We knew we had to act quickly, but we also knew that speed could never compromise the integrity of our science.”
The idea behind this innovative approach originated from the brilliant work of Professors Trimarco, Fiorentino, and Santulli—a team of visionary scientists and physicians whose early insights laid the foundation for what would become a significant clinical breakthrough. Building upon their research, the team at Farmaceutici Damor, under Barbara’s R&D leadership, moved decisively to design and execute a rigorous study to test Bioarginina®’s effectiveness in patients.
The results were remarkable: patients receiving Bioarginina® supplementation experienced a reduced need for respiratory support and shorter hospital stays.
Barbara emphasizes that the success of this project was not just about the data. “It was about seeing a tangible difference in patient outcomes,” she says. “Every reduced ICU stay, every patient who avoided ventilation—that’s what made this work meaningful.”
Beyond the immediate clinical impact, the Bioarginina® study demonstrated Damor’s ability to pivot quickly and innovatively in a crisis. For Barbara, it reinforced a core belief: size and resources are not the sole determinants of impact in healthcare. Agility, scientific rigor, and a clear vision can empower even smaller companies to achieve breakthroughs that resonate globally.
“The pandemic tested every aspect of our team—our resilience, our creativity, and our commitment to patients,” she reflects. “Bioarginina® showed that even under pressure, we could respond with science, compassion, and speed.”
This achievement remains a profound point of pride for Barbara and her colleagues. It reflects not only the potential of their research but also the collaborative culture of innovation and scientific integrity that Barbara has helped foster at Farmaceutici Damor—one that continues to drive the company’s mission forward, even in the most challenging of times.
The Advantage of Agility
For Barbara Maglione, one of Farmaceutici Damor’s greatest strengths lies in its agility. Unlike larger pharmaceutical companies weighed down by layers of bureaucracy, Damor can make decisions quickly, adapt to emerging needs, and invest in projects that might be considered too niche or risky elsewhere.
“Our agility allows us to act on opportunities before they slip away,” Barbara explains. “We can focus on early-stage drug discovery, explore new therapeutic areas, and move from concept to clinical trial faster than many larger organizations.”
This flexibility informs the company’s R&D strategy, which prioritizes precision over blockbuster ambitions. Rather than chasing only high-profile drugs, Damor focuses on areas where its expertise can make a meaningful difference. Barbara emphasizes that this approach allows the team to tackle unmet medical needs and develop therapies that might otherwise be overlooked.
“Being smaller doesn’t mean thinking small,” she says. “We’re able to take calculated risks, innovate rapidly, and apply our knowledge where it can have the most impact. That’s how real breakthroughs happen.”
Barbara believes that agility also fosters a culture of responsibility paired with creativity. Scientists are empowered to explore unconventional ideas, knowing they have the support and structure to test, refine, and advance promising therapies efficiently.
“Ultimately, our goal is not just to develop drugs, but to redefine how we discover and deliver them,” Barbara notes. “By combining our legacy of human-centered science with operational flexibility, we can bring meaningful solutions to patients faster than ever before.”
Farmaceutici Damor’s ability to blend speed, precision, and innovation reflects Barbara’s leadership philosophy: that science thrives when excellence meets adaptability, and when every decision is guided by both knowledge and a sense of purpose.
Advice for Young Female Scientists
Barbara Maglione has a message for the next generation of female scientists entering the world of pharmaceutical R&D: embrace your unique perspective, seek mentorship, and advocate for yourself.
“Don’t try to fit a mold,” she advises. “Your experiences as a woman in a male-dominated field are a strength, not a limitation. The perspective you bring can drive innovation in ways others might overlook.”
Mentorship plays a key role in her philosophy. Barbara encourages young scientists to seek guidance from both male and female mentors. “A good mentor believes in your potential and invests time in your growth,” she explains. “They help you navigate challenges, build confidence, and spot opportunities you might not see on your own.”
Equally important, Barbara urges women to be their own advocates. “Don’t wait for opportunities to come to you. Speak up in meetings, take on challenging projects, and make your voice heard. Confidence and competence together are your most powerful tools.”
Barbara reflects on the progress she has seen: countless women proving their worth through their work, breaking barriers not through words alone, but through results. Her advice is rooted in practical wisdom: resilience, curiosity, and proactive engagement will carry young scientists far in their careers.
The Future of R&D at Farmaceutici Damor
Looking ahead, Barbara is optimistic about the future of pharmaceutical research. At Damor, the focus is increasingly on precision medicine—tailoring treatments to the genetic and molecular profile of individual patients—and the application of artificial intelligence to accelerate drug discovery.
“Precision medicine is the future of healthcare,” she explains. “By understanding each patient’s unique biology, we can design therapies that are more effective and safer. AI will help us analyze vast amounts of data, uncover new drug targets, and streamline the discovery process.”
Barbara emphasizes that innovation is not just about technology—it’s about rethinking the process of drug development. “We want to blend our legacy of human-centered science with modern technology,” she says. “Our goal is to not just create medicines, but to innovate how they are discovered, tested, and delivered.”
Her vision is ambitious yet grounded in practicality. By leveraging agility, scientific rigor, and emerging technologies, Barbara believes that even a mid-sized company like Damor can shape the future of healthcare and make a meaningful difference for patients worldwide.
“Science is constantly evolving,” she concludes. “Our mission is to stay ahead, remain curious, and never lose sight of the patients we serve. That’s what drives every decision we make.”
